{"id":"nystatin","rwe":[],"_fda":{"id":"3984f88f-d61f-1fa9-e063-6394a90acb11","set_id":"01b44f91-9b68-464a-9693-b5d3e793bf3c","openfda":{"nui":["N0000175498","M0017172"],"upc":["0308320465159"],"unii":["BDF1O1C72E"],"route":["TOPICAL"],"rxcui":["584414","646456"],"spl_id":["3984f88f-d61f-1fa9-e063-6394a90acb11"],"brand_name":["Nyamyc"],"spl_set_id":["01b44f91-9b68-464a-9693-b5d3e793bf3c"],"package_ndc":["0832-0465-15","0832-0465-30","0832-0465-60"],"product_ndc":["0832-0465"],"generic_name":["NYSTATIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Polyenes [CS]"],"substance_name":["NYSTATIN"],"pharm_class_epc":["Polyene Antifungal [EPC]"],"manufacturer_name":["Upsher-Smith Laboratories, LLC"],"application_number":["ANDA065183"],"is_original_packager":[true]},"version":"12","pregnancy":["Pregnancy Teratogenic Effects Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether theses preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nyamyc® (Nystatin Topical Powder, USP) should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus."],"description":["DESCRIPTION Nystatin is a polyene antifungal antibiotic obtained from Streptomyces nursei. Nyamyc® (Nystatin Topical Powder, USP) is for dermatologic use. Nyamyc® (Nystatin Topical Powder, USP) contains 100,000 USP nystatin units per gram dispersed in talc. Chemical Structure"],"precautions":["PRECAUTIONS General Nyamyc® (Nystatin Topical Powder, USP) should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections. If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens. INFORMATION FOR THE PATIENT Patients using this medication should receive the following information and instructions: The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed. If symptoms of irritation develop, the patient should be advised to notify the physician promptly. Laboratory Tests If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated. Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility. Pregnancy Teratogenic Effects Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether theses preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nyamyc® (Nystatin Topical Powder, USP) should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus. Nursing Mothers It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman. Pediatric Use Safety and effectiveness have been established in the pediatric population from birth to 16 years. [see DOSAGE AND ADMINISTRATION ]. Geriatric Use Clinical studies with nystatin topical powder did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out."],"how_supplied":["HOW SUPPLIED Nyamyc® (Nystatin Topical Powder, USP) 100,000 units nystatin per gram is available as follow: Bottles of 15 g (NDC 0832-0465-15) Bottles of 30 g (NDC 0832-0465-30) Bottles of 60 g (NDC 0832-0465-60) STORAGE Nyamyc® (Nystatin Topical Powder, USP) Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Avoid excessive heat (40°C/104°F). Keep tightly closed. Keep out of reach of children. Nyamyc is a registered trademark of Upsher-Smith Laboratories, LLC."],"microbiology":["Microbiology Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida (C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses."],"geriatric_use":["Geriatric Use Clinical studies with nystatin topical powder did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out."],"pediatric_use":["Pediatric Use Safety and effectiveness have been established in the pediatric population from birth to 16 years. [see DOSAGE AND ADMINISTRATION ]."],"effective_time":"20250709","nursing_mothers":["Nursing Mothers It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is prescribed for a nursing woman."],"laboratory_tests":["Laboratory Tests If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated."],"pharmacokinetics":["Pharmacokinetics Nystatin is not absorbed from intact skin or mucous membrane."],"adverse_reactions":["ADVERSE REACTIONS The frequency of adverse events reported in patients using nystatin topical preparations is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. [see PRECAUTIONS: General ]."],"contraindications":["CONTRAINDICATIONS Nyamyc® (Nystatin Topical Powder, USP) is contraindicated in patients with a history of hypersensitivity to any of its components."],"how_supplied_table":["<table width=\"60%\" styleCode=\"Noautorules\"><col width=\"30%\" align=\"left\" valign=\"top\"/><col width=\"70%\" align=\"left\" valign=\"top\"/><tbody><tr><td> Bottles of 15 g</td><td>(NDC 0832-0465-15)</td></tr><tr><td> Bottles of 30 g</td><td>(NDC 0832-0465-30)</td></tr><tr><td> Bottles of 60 g</td><td>(NDC 0832-0465-60)</td></tr></tbody></table>"],"general_precautions":["General Nyamyc® (Nystatin Topical Powder, USP) should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections. If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens."],"teratogenic_effects":["Teratogenic Effects Animal reproduction studies have not been conducted with any nystatin topical preparation. It also is not known whether theses preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nyamyc® (Nystatin Topical Powder, USP) should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus."],"storage_and_handling":["STORAGE Nyamyc® (Nystatin Topical Powder, USP) Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Avoid excessive heat (40°C/104°F). Keep tightly closed. Keep out of reach of children. Nyamyc is a registered trademark of Upsher-Smith Laboratories, LLC."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Pharmacokinetics Nystatin is not absorbed from intact skin or mucous membrane. Microbiology Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida (C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses."],"indications_and_usage":["INDICATIONS AND USAGE Nyamyc® (Nystatin Topical Powder, USP) is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species. Nyamyc® (Nystatin Topical Powder, USP) is not indicated for systemic, oral, intravaginal or ophthalmic use."],"information_for_patients":["INFORMATION FOR THE PATIENT Patients using this medication should receive the following information and instructions: The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed. If symptoms of irritation develop, the patient should be advised to notify the physician promptly."],"spl_unclassified_section":["100,000 units per gram Rx only FOR TOPICAL USE ONLY • NOT FOR OPHTHALMIC USE","Manufactured by UPSHER-SMITH LABORATORIES, LLC Maple Grove, MN 55369 Revised: 6/2024"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Very moist lesions are best treated with the topical dusting powder. Adults and Pediatric Patients (Neonates and Older) Apply to candidal lesions two or three times daily until healing is complete. For fungal infection of the feet caused by Candida species, the powder should be dusted on the feet, as well as, in all foot wear."],"spl_product_data_elements":["Nyamyc Nystatin TALC NYSTATIN NYSTATIN"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 15 gram Bottle Carton NDC 0832-0465-15 Nyamyc ® Nystatin Topical Powder, USP 100,000 USP units per gram FOR TOPICAL USE ONLY. NOT FOR OPHTHALMIC USE. NET WT. 15 grams Rx only UPSHER-SMITH label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility."]},"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"1969 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1808 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"1794 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"1616 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"1483 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"1383 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"1333 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"1270 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"1261 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"1190 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"","severity":"common","organSystem":""},{"effect":"Polydipsia","drugRate":"","severity":"common","organSystem":""},{"effect":"Polyuria","drugRate":"","severity":"common","organSystem":""},{"effect":"SAP enzyme elevation","drugRate":"","severity":"common","organSystem":""},{"effect":"SGPT (ALT) enzyme elevation","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Adrenal cortical hypofunction","Atrophoderma","Telangiectasia disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Cushing's syndrome","drugRate":"","severity":"serious"},{"effect":"Hearing loss","drugRate":"","severity":"serious"},{"effect":"Bloody diarrhea","drugRate":"","severity":"serious"}]},"status":"approved","trials":["NCT02186145","NCT04768829","NCT02208154","NCT01198223","NCT00814359","NCT06637423","NCT00942526","NCT02444481","NCT04837664","NCT03237533","NCT00002112","NCT02142543","NCT00250133","NCT00002057","NCT00001812","NCT00845819","NCT00002742","NCT01495039","NCT05894954","NCT00002313","NCT04550546","NCT03320460","NCT01531192","NCT00002293","NCT02642900","NCT00634166","NCT04438174","NCT05648682","NCT01867164","NCT01411748","NCT06356311","NCT04118335","NCT06616168","NCT06049511","NCT01886001","NCT01111942","NCT04532060","NCT00659971","NCT00674999","NCT01718912","NCT01893060","NCT03178149","NCT02389036","NCT03390374","NCT06875791","NCT00128323","NCT01524744","NCT02662374","NCT03399331","NCT00629122"],"aliases":["Mycostatin","Nystop","Bio-Statin"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=nystatin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:07:28.742955+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:07:59.390441+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:07:35.365101+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:07:27.360764+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=nystatin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:07:36.150587+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:07:26.298770+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:07:26.298815+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:07:47.887594+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:07:26.298829+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:07:37.739719+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Ergosterol sequestering agent","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:07:36.756205+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5465559/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:07:36.619455+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA065183","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:07:26.298838+00:00"}},"allNames":"mycostatin","offLabel":[],"timeline":[],"aiSummary":"Nystatin (Mycostatin) is a generic polyene antifungal marketed for cutaneous or mucocutaneous mycotic infections, originally developed by Squibb. Its key strength lies in its mechanism of action, which involves binding ergosterol in fungal cell membranes to create pores leading to cell death, and it is not absorbed systemically, minimizing systemic side effects. The primary risk is the key composition patent expiry in 2028, which could increase competition from other generics.","brandName":"Mycostatin","companyId":"unknown","ecosystem":[],"mechanism":{"target":"Ergosterol (fungal cell membrane)","novelty":"","modality":"Small molecule (natural product)","drugClass":"Polyene Antifungal [EPC]","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"_validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T01:07:59.390908+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"companyName":"Generic (originally Squibb)","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"nystatin","indications":{"approved":[{"id":"nystatin-cutaneous-or-mucocutaneous-myc","name":"Cutaneous or Mucocutaneous Mycotic Infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species","diagnosticRequired":null,"brandNameForIndication":"Mycostatin"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT02186145","phase":"Phase 3","title":"Single Blind Randomized Study of Efficacy and Safety of Vaginal Cream With Association of Metronidazole, Nystatin and Dexamethasone in the Treatment of Bacterial and Fungal Vaginal Infections","status":"UNKNOWN","sponsor":"Marjan Industria e Comercio ltda","isPivotal":true,"enrollment":160,"indication":"Bacterial Vaginosis, Fungal Vaginal Infections","completionDate":"2017-01"},{"nctId":"NCT04768829","phase":"EARLY/Phase 1","title":"Antifungal Potential of Moringa Olifera-loaded Nanoparticles Against Otomycosis; Preparation, Characterization, and Clinical Evaluation","status":"COMPLETED","sponsor":"Deraya University","isPivotal":false,"enrollment":10,"indication":"Otomycosis","completionDate":"2021-12-01"},{"nctId":"NCT02208154","phase":"Phase 3","title":"RGNOSIS: Ecological Effects of Decolonisation Strategies in Intensive Care","status":"COMPLETED","sponsor":"MJM Bonten","isPivotal":true,"enrollment":8665,"indication":"ICU-ecology (Multidrug Resistant Bacteria), ICU-acquired Bacteraemia","completionDate":"2017-10-27"},{"nctId":"NCT01198223","phase":"Phase 2","title":"Comparison of Therapeutic Effect of Aqueous Extract of Garlic and Nystatin Mouthwash in Denture Stomatitis","status":"COMPLETED","sponsor":"Qazvin University Of Medical Sciences","isPivotal":false,"enrollment":40,"indication":"Denture Stomatitis","completionDate":"2010-10"},{"nctId":"NCT00814359","phase":"Phase 3","title":"A Phase III Study of Magic Mouthwash Plus Sucralfate Versus Benzydamine HCl for Treatment of Radiation-induced Oral Mucositis in Head and Neck Cancer Patients.","status":"COMPLETED","sponsor":"Juravinski Cancer Centre Foundation","isPivotal":true,"enrollment":67,"indication":"Head and Neck Cancer, Mucositis","completionDate":"2010-09"},{"nctId":"NCT06637423","phase":"Phase 1","title":"A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder ","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","isPivotal":false,"enrollment":32,"indication":"Non-Muscle Invasive Bladder Cancer","completionDate":"2028-07-31"},{"nctId":"NCT00942526","phase":"Phase 2","title":"The Correlation of Oral Anti-Infective Agent With Anastomotic Leakage in Reconstruction Surgery for Esophageal Cancer","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","isPivotal":false,"enrollment":120,"indication":"Anastomotic Leakage","completionDate":"2010-12"},{"nctId":"NCT02444481","phase":"Phase 4","title":"Open Multicenter Clinical Study of the Efficacy of the Local Treatment With Polygynax of Mycotic and/or Bacterial Vaginitis","status":"COMPLETED","sponsor":"Laboratoire Innotech International","isPivotal":false,"enrollment":169,"indication":"Vaginitis","completionDate":"2009-11"},{"nctId":"NCT04837664","phase":"Phase 3","title":"Efficacy of Rose Bengal and Curcumin Mediated Photodynamic Therapy in the Treatment of Denture Stomatitis in Patients With Habitual Cigarette Smokers: a Randomized Controlled Clinical Trial","status":"UNKNOWN","sponsor":"King Saud University","isPivotal":true,"enrollment":45,"indication":"Candida Albicans Infection, Cigarette Smoking","completionDate":"2021-05-01"},{"nctId":"NCT03237533","phase":"EARLY/Phase 1","title":"Comparative Efficacy of Dexamethasone, Doxycycline, Nystatin and Promethazine With Triamcinolone in Orabase as Symptomatic Treatment of Oral Lichen Planus, A Randomized Controlled Trial","status":"UNKNOWN","sponsor":"University of Faisalabad","isPivotal":false,"enrollment":32,"indication":"Oral Lichen Planus","completionDate":"2017-12-31"},{"nctId":"NCT00002112","phase":"NA","title":"Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Associati","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":0,"indication":"Candidiasis, Oral, HIV Infections","completionDate":""},{"nctId":"NCT02142543","phase":"EARLY/Phase 1","title":"The Effect of 2-DeNT Oral Topical Powder on Minor Recurrent Aphthous Ulcer","status":"COMPLETED","sponsor":"Texas A&M University","isPivotal":false,"enrollment":23,"indication":"Minor Recurrent Aphthous Stomatitis Lesions","completionDate":"2012-12"},{"nctId":"NCT00250133","phase":"N/A","title":"Microbiologic Effect of Selective Decontamination of the Digestive Tract With Colistin, Gentamicin and Nystatin","status":"TERMINATED","sponsor":"University of Pittsburgh","isPivotal":false,"enrollment":40,"indication":"VRE Colonization","completionDate":""},{"nctId":"NCT00002057","phase":"NA","title":"Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","isPivotal":false,"enrollment":0,"indication":"Candidiasis, Oral, HIV Infections","completionDate":""},{"nctId":"NCT00001812","phase":"Phase 3","title":"A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":true,"enrollment":84,"indication":"Candidiasis, Oral, Gastrointestinal Diseases","completionDate":"2000-08"},{"nctId":"NCT00845819","phase":"Phase 2","title":"Randomized Phase II Study of Recombinant Human Epidermal Growth Factor (rhEGF) on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies","status":"COMPLETED","sponsor":"Seoul National University Hospital","isPivotal":false,"enrollment":138,"indication":"Oral Mucositis","completionDate":"2014-10"},{"nctId":"NCT00002742","phase":"Phase 3","title":"A PROSPECTIVE RANDOMIZED, DOUBLE-BLIND, COMPARATIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF NYSTATIN AND AMPHOTERICIN B FOR EMPIRIC ANTIFUNGAL TREATMENT IN NEUTROPENIC PATIENTS","status":"COMPLETED","sponsor":"Aronex Pharmaceuticals","isPivotal":true,"enrollment":0,"indication":"Chronic Myeloproliferative Disorders, Infection","completionDate":"2007-09"},{"nctId":"NCT01495039","phase":"Phase 4","title":"The Role of Oral Nystatin Prophylaxis in ICU Surgical/Trauma Patients","status":"COMPLETED","sponsor":"Policlinico Hospital","isPivotal":false,"enrollment":99,"indication":"Fungal Prophylaxis, Candida Infection","completionDate":"2010-02"},{"nctId":"NCT05894954","phase":"Phase 3","title":"EVANTHEA TRIAL: A Pragmatic, Randomized, Controlled Trial to Evaluate the Effectiveness of a Precision Medicine Treatment Approach for Early Dementia and Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","isPivotal":true,"enrollment":73,"indication":"Mild Cognitive Impairment, Dementia, Mild","completionDate":"2026-02-09"},{"nctId":"NCT00002313","phase":"Phase 1","title":"Extended Maintenance Protocol for Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection (NOTE: Continuation Study Intended Only for Patients Who Have Completed FDA 10","status":"COMPLETED","sponsor":"Argus Pharmaceuticals","isPivotal":false,"enrollment":0,"indication":"HIV Infections","completionDate":""},{"nctId":"NCT04550546","phase":"Phase 1","title":"Effects of Nystatin Suspension Oral Application on Oral Microbial Community","status":"COMPLETED","sponsor":"University of Rochester","isPivotal":false,"enrollment":20,"indication":"Dental Caries","completionDate":"2022-02-28"},{"nctId":"NCT03320460","phase":"NA","title":"Efficacy of Photobiomodulation for Oral Lichen Planus Treatment","status":"UNKNOWN","sponsor":"University of Nove de Julho","isPivotal":false,"enrollment":44,"indication":"Lichen Planus, Oral, Low-Level Light Therapy","completionDate":"2020-12"},{"nctId":"NCT01531192","phase":"Phase 4","title":"Zekai Tahir Burak Maternity Teaching Hospital, Ankara/Turkey","status":"COMPLETED","sponsor":"Zekai Tahir Burak Women's Health Research and Education Hospital","isPivotal":false,"enrollment":300,"indication":"Very Low Birth Weight Infants","completionDate":"2013-04"},{"nctId":"NCT00002293","phase":"NA","title":"Nystatin Pastille for the Prophylaxis of Oral Candidiasis in Patients With AIDS or AIDS Related Syndromes","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","isPivotal":false,"enrollment":0,"indication":"Candidiasis, Oral, HIV Infections","completionDate":""},{"nctId":"NCT02642900","phase":"Phase 4","title":"Photodynamic Therapy Against Candida Spp. in Complete Denture Wearers: a Randomized Clinical Trial","status":"COMPLETED","sponsor":"University of Sao Paulo","isPivotal":false,"enrollment":22,"indication":"Photochemotherapy Reaction","completionDate":"2011-07"},{"nctId":"NCT00634166","phase":"Phase 4","title":"Prospective Evaluation of the Effects of Topical Therapy With Sulfamylon® For 5% Topical Solution on Autograft Healing in Subjects With Thermal Injuries Requiring Meshed Autografts: A Comparison to a ","status":"TERMINATED","sponsor":"Mylan Inc.","isPivotal":false,"enrollment":220,"indication":"Burns","completionDate":"2014-04"},{"nctId":"NCT04438174","phase":"Phase 1","title":"A Phase I/II Clinical Trial To Determine Safety And Feasibility Of Using An Acellular Amniotic Fluid Application To Expedite Healing In Chronic Wounds","status":"TERMINATED","sponsor":"University of Utah","isPivotal":false,"enrollment":1,"indication":"Wounds and Injuries","completionDate":"2023-03"},{"nctId":"NCT05648682","phase":"NA","title":"Comparison of the Effectiveness of Three Different Gargates in Radiotherapy-Associated Oral Mucositis Management in Head and Neck Cancer Patients: A Randomized Controlled Study","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi Gulhane Tip Fakultesi","isPivotal":false,"enrollment":48,"indication":"Head and Neck Cancers, Oral Mucositis","completionDate":"2022-01-01"},{"nctId":"NCT01867164","phase":"Phase 3","title":"A Prospective, Open-Label, Comparative, Parallel Double-Arm, Multicentric Clinical Study to Evaluate the Efficacy of an Ovule With Triple Active Agents (Terconazole, Clindamycin, Fluocinolone) Adminis","status":"COMPLETED","sponsor":"Janssen-Cilag, S.A.","isPivotal":true,"enrollment":160,"indication":"Vaginitis, Infectious Vaginosis","completionDate":"2008-12"},{"nctId":"NCT01411748","phase":"Phase 4","title":"","status":"UNKNOWN","sponsor":"Zekai Tahir Burak Women's Health Research and Education Hospital","isPivotal":false,"enrollment":140,"indication":"Anticandidal Property of Saccharomyces Boulardii on Very Low Birth Weight Infants","completionDate":"2011-12"},{"nctId":"NCT06356311","phase":"Phase 3","title":"A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Ga","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","isPivotal":true,"enrollment":450,"indication":"Gastroesophageal Cancer","completionDate":"2027-05-06"},{"nctId":"NCT04118335","phase":"NA","title":"The Effect of Oral Care by Black Mulberry Syrup on Oral Mucositis in Individuals With COPD","status":"COMPLETED","sponsor":"TC Erciyes University","isPivotal":false,"enrollment":40,"indication":"Oral Mucositis","completionDate":"2018-06-28"},{"nctId":"NCT06616168","phase":"Phase 1","title":"Ministry of Health of Ukraine No. 2264 from 15.12.2022, Ministry of Health of Ukraine No. 310 from 08.05.2014, Ministry of Health of Ukraine No. 928 from 18.05.2023","status":"ACTIVE_NOT_RECRUITING","sponsor":"Danylo Halytsky Lviv National Medical University","isPivotal":false,"enrollment":200,"indication":"Bacterial Vaginosis","completionDate":"2027-08-31"},{"nctId":"NCT06049511","phase":"NA","title":"The Effect of the Oral Self-Care Protocol on Mucositis and Self-Care Agency According to Orem's Self-Care Deficiency Theory in Patients With Hematologic Malignancies Receiving High-Dose Chemotherapy: ","status":"COMPLETED","sponsor":"Ege University","isPivotal":false,"enrollment":60,"indication":"Mucositis Oral","completionDate":"2022-12-28"},{"nctId":"NCT01886001","phase":"NA","title":"Topical Umbilical Cord Care for the Prevention of Colonization and Invasive Infections","status":"COMPLETED","sponsor":"University of Virginia","isPivotal":false,"enrollment":53,"indication":"Colonization","completionDate":"2013-07"},{"nctId":"NCT01111942","phase":"EARLY/Phase 1","title":"A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer","status":"TERMINATED","sponsor":"Southern Illinois University","isPivotal":false,"enrollment":4,"indication":"Head and Neck Cancer","completionDate":"2014-01"},{"nctId":"NCT04532060","phase":"Phase 2","title":"A Randomized Clinical Trial Evaluating Chlorine e6 Derivative-mediated Antimicrobial Photodynamic Therapy as a Treatment for Denture Stomatitis","status":"COMPLETED","sponsor":"São Paulo State University","isPivotal":false,"enrollment":65,"indication":"Health Care Associated Infection","completionDate":"2017-05-02"},{"nctId":"NCT00659971","phase":"Phase 2","title":"A Phase 2B Dose-Ranging Study of PAC113 Mouthrinse for Clinical and Microbial Evaluation in HIV Seropositive Individuals With Oral Candidiasis to Establish the Optimal Dose of PAC113","status":"COMPLETED","sponsor":"Pacgen Biopharmaceuticals Corporation","isPivotal":false,"enrollment":223,"indication":"Oral Candidiasis","completionDate":"2008-06"},{"nctId":"NCT00674999","phase":"Phase 2","title":"Project Title The Treatment of Partial Thickness Burns: Treated Amnion Versus Currently in Use Topical Medications","status":"WITHDRAWN","sponsor":"The University of Texas Medical Branch, Galveston","isPivotal":true,"enrollment":0,"indication":"Burn","completionDate":"2008-09"},{"nctId":"NCT01718912","phase":"NA","title":"The Effect of an Antibiotic-antifungal Rinse on Periodontal Disease","status":"COMPLETED","sponsor":"Oravital Inc","isPivotal":false,"enrollment":11,"indication":"Periodontal Disease","completionDate":"2014-10"},{"nctId":"NCT01893060","phase":"NA","title":"Umbilical Cord Care for the Prevention of Colonization","status":"UNKNOWN","sponsor":"University of Virginia","isPivotal":false,"enrollment":100,"indication":"Line Insertion Site, Central Line-associated Bloodstream Infection (CLABSI)","completionDate":"2014-07"},{"nctId":"NCT03178149","phase":"Phase 1","title":"A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age-related Macular Degeneration","status":"RECRUITING","sponsor":"Astellas Institute for Regenerative Medicine","isPivotal":false,"enrollment":42,"indication":"Age-Related Macular Degeneration","completionDate":"2026-06-30"},{"nctId":"NCT02389036","phase":"Phase 3","title":"A Crossover, Cluster Randomised Controlled Trial of Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients (SuDDICU)","status":"COMPLETED","sponsor":"The George Institute","isPivotal":true,"enrollment":20010,"indication":"Critical Illness, Sepsis","completionDate":"2023-04-26"},{"nctId":"NCT03390374","phase":"Phase 4","title":"Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants: a Randomized Controlled Trial","status":"COMPLETED","sponsor":"Dr Cipto Mangunkusumo General Hospital","isPivotal":false,"enrollment":95,"indication":"Fungal Infections Systemic","completionDate":"2013-01"},{"nctId":"NCT06875791","phase":"Phase 1","title":"A Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Patients Undergoing Treatment for Head and Neck Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fundacion Clinica Valle del Lili","isPivotal":false,"enrollment":40,"indication":"Squamous Cell Carcinoma of the Head and Neck, Oral Mucositis","completionDate":"2026-12-31"},{"nctId":"NCT00128323","phase":"Phase 3","title":"A Comparison of Gentian Violet Mouth Washes, Nystatin Drops and Ketoconazole Tabs in the Treatment of Oropharyngeal Candidiasis","status":"COMPLETED","sponsor":"Kamuzu University of Health Sciences","isPivotal":true,"enrollment":558,"indication":"Candidiasis, Oral","completionDate":"2005-04"},{"nctId":"NCT01524744","phase":"Phase 2","title":"","status":"UNKNOWN","sponsor":"Mashhad University of Medical Sciences","isPivotal":false,"enrollment":40,"indication":"Oral Lichen Planus","completionDate":"2012-12"},{"nctId":"NCT02662374","phase":"Phase 4","title":"Efficacy of Two Different Oral Hygiene Regimens on the Incidence and Severity of Oral Mucositis in Patients Receiving Hematopoietic Stem Cell Transplantation - A Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Riyadh Colleges of Dentistry and Pharmacy","isPivotal":false,"enrollment":45,"indication":"Oral Mucositis","completionDate":"2016-05"},{"nctId":"NCT03399331","phase":"Phase 1","title":"\"The Efficacy of Honey or Olive Oil on the Severity and Pain of Oral Mucositis Compared to Placebo (Standard Care) in Children With Leukemia Receiving Intensive Chemotherapy","status":"COMPLETED","sponsor":"American University of Beirut Medical Center","isPivotal":false,"enrollment":45,"indication":"Oral Mucositis, Leukemia","completionDate":"2024-06-01"},{"nctId":"NCT00629122","phase":"Phase 4","title":"Pharmacokinetic Evaluation of Sublingual Versus Oral Tacrolimus Administration in Patients Awaiting Kidney Transplantation","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","isPivotal":false,"enrollment":5,"indication":"Kidney Failure, Chronic","completionDate":"2009-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Topical","frequency":"Four times daily","formulation":"Oral suspension, Tablet, Cream, Ointment, Powder"},"crossReferences":{"chemblId":"CHEMBL5465559"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":4529,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"firstApprovalDate":"1954-01-01","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Small molecule (natural product)","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1996-04-30T00:00:00.000Z","mah":"SUN PHARMA CANADA","brand_name_local":null,"application_number":"ANDA064022"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2005-05-03T00:00:00.000Z","mah":"UPSHER SMITH LABS","brand_name_local":null,"application_number":"ANDA065183"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-10-06T00:00:00.000Z","mah":"COSETTE","brand_name_local":null,"application_number":"ANDA209114"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-01-28T00:00:00.000Z","mah":"TORRENT","brand_name_local":null,"application_number":"ANDA211838"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-07-24T00:00:00.000Z","mah":"TORRENT","brand_name_local":null,"application_number":"ANDA212557"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":2,"lastValidatedAt":"2026-04-20T01:07:59.390908+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}